Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Pancreatic Ductal 1

Interventions

Gemcitabine 8130-nm albumin-bound paclitaxel 5Albumin-Bound Paclitaxel 4napabucasin 2Oxaliplatin 2MK-4721 2Leucovorin 2Fluorouracil 2Carboplatin 2tremelimumab 1irinotecan sucrosofate 1ensituximab 1durvalumab 1contrast agent BR1 1cc-486 1Taxes 1Practice Guidelines as Topic 1Pancreaticoduodenectomy 1Paclitaxel 1PEGPH20 1Lead 1Irinotecan 1Enoxaparin 1EC regimen 1Drug Therapy 1Dexamethasone 1Cisplatin 1CP protocol 1Azacitidine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Pancreatic Ductal × ensituximab × Clear all
NCT01040000 2017-08-04

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Precision Biologics, Inc

Phase 1/2 Completed
94 enrolled
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡